Evaluating revascularization and flap survival using vascular endothelial growth factor in an irradiated rat model

Arch Facial Plast Surg. 2011 May-Jun;13(3):185-9. doi: 10.1001/archfacial.2010.115. Epub 2011 Jan 17.

Abstract

Objective: To evaluate the role of vascular endothelial growth factor (VEGF) plasmid DNA (pDNA) in improving flap revascularization in a previously developed rat model. Our hypothesis was that the uptake and expression of VEGF pDNA in the wound bed would improve revascularization and flap viability.

Design: Twenty-eight male Sprague-Dawley rats received a total dose of 40 Gy electron beam radiation to the ventral abdominal wall. After a recovery period, they underwent a ventral fasciocutaneous flap procedure with a 2-hour ischemia period. Group 1 (n = 14) received topical VEGF pDNA, in vivo cationic polymer, and fibrin sealant. Group 2 (n = 14) received topical cationic polymer and fibrin sealant only. Seven of the rats from each group underwent pedicle ligation at 8 or 14 days. The primary outcome measure was percentage of flap revascularization 5 days after pedicle ligation.

Results: Rats receiving VEGF pDNA had a significantly higher rate of flap revascularization (90.8% vs 79.8%) after pedicle ligation at 14 days (P = .045). At 8 days, rats receiving VEGF pDNA (group 1) had an increased rate of flap revascularization (58.2% vs 42.8%) that approached significance (P = .11).

Conclusion: This study demonstrates the potential of VEGF pDNA to improve revascularization and flap viability in previously irradiated tissue.

MeSH terms

  • Administration, Cutaneous
  • Animals
  • Free Tissue Flaps / blood supply*
  • Gene Expression
  • Gene Transfer Techniques*
  • Graft Survival / drug effects*
  • Graft Survival / radiation effects
  • Male
  • Models, Animal
  • Plasmids*
  • Rats
  • Rats, Sprague-Dawley
  • Vascular Endothelial Growth Factors / genetics*
  • Vascular Endothelial Growth Factors / pharmacology

Substances

  • Vascular Endothelial Growth Factors